PCSK9 medication is an innovative treatment that has the potential to directly mitigate the factors contributing to CAD by reducing vascular inflammation and inhibiting the TLR4/NF-κB signalling pathway. PCSK9 may serve as an inflammatory mediator in the development of atherosclerosis, a primary underlying cause of CAD. This evidence concerns the gene TLR4 and atherosclerosis.